Adicet Bio (ACET) “announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. Truist Securities is also acting as a joint bookrunner. Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Announces Major Stock Offering Agreement
- Adicet Bio Reports Promising Phase 1 Study Results
- Adicet Bio’s ADI-001 shows positive preliminary Phase 1 results in LN and SLE
- Adicet Bio’s Promising CAR γδ T Cell Therapy: A Buy Rating Amidst Anticipated Breakthroughs in Lupus Treatment
- Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating